Form D · Biotechnology
Gemina Laboratories Ltd.
Burnaby, A1 · CIK 0001940016
Offering snapshot reported Apr 1, 2024 · SEC filing
- Reported sold
- $303K Offering amount: $303K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 18, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 1, 2024 | Initial | $302,784 | No comparison | 2 | SEC filing |
| Aug 8, 2022 | Initial | $370,400 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-509168
CAD$1,3541 = USD$1.00
Debt convertible into Issuer common shares without additional consideration.
Source: Form D, filed Apr 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Martin Cronin | Director |
| John Davies | Director |
| Brian Firth | Director, Executive |
| Bola Grace | Director |
| Robert Greene | Director, Executive |
| Rob Greene | Director, Executive |
| Mike Liggett | Executive |
| Michael Liggett | Executive |
| Martha Najib | Director |
| Davis Rokoss | Director, Executive |
| James Tansey | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3600 Gilmore Way, Suite 302
Burnaby, A1, V5G 4R8
Burnaby, A1, V5G 4R8